GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Rhea-AI Summary
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in A.G.P.'s Annual Healthcare Company Showcase. CEO Marc Hertz, PhD will engage in a fireside chat on Wednesday, May 21, 2025, at 2:40 PM ET. The virtual event will be accessible via webcast through the Events page in the Investors section of GRI Bio's website.
Positive
- None.
Negative
- None.
News Market Reaction – GRI
On the day this news was published, GRI gained 3.45%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET
LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET.
Click here to register for the event. A live webcast of the fireside chat will be accessible on the Events page under the Investors section of the Company’s website (gribio.com).
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What is GRI Bio's main focus in drug development?
When is GRI Bio's presentation at A.G.P.'s Healthcare Company Showcase?
How can investors access GRI Bio's presentation at A.G.P.'s Healthcare Showcase?
Who will be presenting for GRI Bio at the A.G.P. Healthcare Showcase?
